John Chang

Prostate Cancer Foundation of Australia

Papers

1

Total Citations

40

H-Index

1

About

Dr. John Chang is a pioneering urologic oncologist whose research centers on advancing minimally invasive treatments for prostate cancer, with a particular focus on balancing oncological control with quality of life. His landmark 2018 study, which has garnered 40 citations, directly compared patient-reported outcomes following focal irreversible electroporation (IRE) versus robot-assisted radical prostatectomy (RARP). This work was groundbreaking in addressing the inherent challenges of conducting randomized trials for curative prostate cancer treatments, offering real-world evidence that IRE may preserve quality of life without compromising early oncological control. Dr. Chang’s contributions are especially significant in an era where treatment side effects profoundly impact patients’ lives; his research provides critical data for shared decision-making between men and their clinicians. By rigorously evaluating novel focal therapies against the gold standard of surgery, he has helped define the role of IRE in the prostate cancer treatment landscape. His work continues to influence urologic practice, bridging the gap between technological innovation and patient-centered outcomes.

Research Focus

Key Achievements

1
H-Index
1
Papers
40
Total Citations
40
Avg Citations/Paper
🏆 Most Cited Paper
Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy
40 citations · 2018
📈 Most Prolific Year: 2018 (1 Papers)
🤝 Key Collaborators: 13
🏛 Institutions: Prostate Cancer Foundation of Australia

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago